Preview: Analysis of Nuvilex Inc. :

Company Describtion:

Nuvilex is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the widely used anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. Nuvilex is also working towards clinical trials associated with the symptoms of advanced pancreatic cancer and other abdominal cancers. 

Nuvilex's subsidiary, Medical Marijuana Sciences, is dedicated to the development of cancer treatments based upon chemical constituents of the Cannabis plant known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or eliminating the debilitating side effects usually associated with traditional cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.

Interesting fact you might not know about Nuvilex Inc.:

Nuvilex is currently held by Ken Fisher of Fisher Asset Management. He is the son of the legendary investor Phillip A Fisher. The investment philosophy at Fisher Investments is based on the idea that supply and demand of securities is the sole determinate of their pricing. The way to add value is to identify information not widely known or to interpret widely known information differently and correctly from other market participants. He purchased 11,300 shares in the first quarter of 2013, the same quarter that the subsidiary Medical Marijuana Sciences, Inc was incorporated. His purchase was a very small one that amounted to about $500 at the time. Today it is valued at about $3000. Even though it was a small purchase, it helps bring some credibility to the company and helps separate it from the possible scams.

A detailed full analysis of this stock will be posted here next week.

Sources: 

gurufocus.com 

Nuvilex.com

Disclaimer

Past performance is no guarantee of future success and you should not assume that the securities of companies in our newsletter, on our website or mentioned in electronic communications will perform better than or even equal to the performance of the securities of companies profiled or mentioned previously. You alone are responsible for your own investment decisions. The information presented has been obtained from sources believed to be reliable, but accuracy cannot be guaranteed.  Any and all earnings projections and estimates assume certain economic conditions and industry developments, which are subject to change. You should independently verify all information generated on this website and/or sent via electronic distribution. You should consider obtaining professional advice before making any investment decision. Investing in small and micro-cap stocks can lead to loss of investment and is not appropriate for all investors. All stock investments carry some degree of risk. By investing in any of the stocks of the companies profiled or mentioned on our website, in our newsletter or by electronic communication you can and may lose some or all of your investment. Do not invest in any stock if you are not prepared to lose your entire investment. Small and micro-cap stocks can be highly volatile. High volatility securities may experience sudden and large falls in their value, leading to losses. Small and micro-cap stocks may be difficult to sell due to a lack of liquidity. The author of this blog post may hold positions in the securities that are discussed in our newsletter, on our website or delivered via electronic communication. These securities can be bought or sold at any time, without restriction.